Brief: Kintor Pharma- Ar-Protac (Gt20029) Approved For Acne And Androgenic Alopecia Clinical Trials In China
15/04/2021 11:23
April 15 (Reuters) - Kintor Pharmaceutical Ltd 9939.HK :
* KINTOR PHARMACEUTICAL ANNOUNCES AR-PROTAC (GT20029)
APPROVED FOR
ACNE AND ANDROGENIC ALOPECIA CLINICAL TRIALS IN CHINA
Source text for Eikon: ID:nPnc1GbZJa
Further company coverage: 9939.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kintor Pharmaceutical
See all newsBrief: Kintor Pharmaceutical Receives Invention Patent Grant For KT-939 In China
Brief: Kintor Pharmaceutical Says Ming Ming Cheung Resigns As CFO
Brief: Kintor Pharmaceutical Says CEO Via Wholly Owned Co Increases Shareholding By 2.51 Million Shares
Brief: Kintor Pharmaceutical Says YTD 2026 Sales Revenue At RMB34 Million
Brief: Kintor Pharmaceutical Says Pharma's Kx-826 Phase Iii Trial In China Reaches Primary Endpoint